September 13, 2013
Given the growing number of pharma companies in China under investigation for bribery and corruption, it’s becoming more a question of who isn’t being investigated, rather than who is.
Pharma companies currently under investigation by Chinese authorities include:
- Bayer AG
- GlaxoSmithKline
- Novo Nordisk A/S
- Sanofi SA
- Eli Lilly
- Sino Biopharmaceuticals
- AstraZeneca
- UCB
Bayer gets a quarter of its global revenue from the Asia-Pacific region, according to Reuters.